zasocitinib — NDA/BLA submission
FY2026
We completed regulatory filings for oveporexton in the U.S., Japan and China, and for rusfertide in the U.S.; zasocitinib will be filed in FY2026.Source filing
TAK biotech catalysts & pipeline
TAKEDA PHARMACEUTICAL CO LTD · Data as of 2026-09-08